Harvard's 'Guppy Tank': A Unique Approach to Medical Investor Pitches

Understanding the Concept Behind ‘Guppy Tank’

Jeffrey Smith, an assistant professor of dermatology at Harvard Medical School and Brigham and Women’s Hospital, is exploring a new therapeutic avenue aimed at enhancing melanin levels in the skin. This drug could significantly benefit individuals suffering from extreme sun sensitivity, such as those with porphyria, who risk severe burns from minimal sun exposure.

Smith’s Presentation and Feedback

During his presentation at ‘Guppy Tank’, an inventive alternative to traditional investor pitches like ABC’s “Shark Tank,” Smith sought insight on various facets of his project. The event, organized by the Harvard Office of Technology Development alongside LabCentral, allowed entrepreneurs to receive constructive feedback without the usual pressure of immediate decision-making.

Unlike the typical intense atmosphere of venture capital, this session aimed for a supportive exchange. “We’re hopeful that the comments are more guppy than shark,” remarked Grant R. Zimmermann, managing director of business development for the Blavatnik Biomedical Accelerator.

Smith outlined his proposal, which he developed with Andrew Kruse, a colleague from Harvard. “We have a melanocortin-1 receptor agonist that can tan the skin,” he stated confidently, introducing the potential benefits of the treatment.

Existing Solutions and Innovations

This novel approach is notable, although it's not the first of its kind. An existing therapy effectively manages porphyria through the same biological pathway; however, it has drawbacks such as a significant nausea rate in 46% of users and a complicated regimen requiring multiple implants each year. In contrast, Smith and Kruse’s treatment could offer a more user-friendly option with an injection administered once every six months.

In terms of broader implications, Smith envisions applications beyond just porphyria. For instance, he cited skin cancer prevention and the rare genetic disorder xeroderma pigmentosum (XP), which greatly increases skin cancer rates in affected individuals.

Panel Insights and Considerations

The panelists provided insights on potential clinical targets, dosage considerations, and the insurance landscape affecting the future of Smith’s drug. Mike Schlabach from Curie Bio emphasized the importance of demonstrating significant quality-of-life improvements in animal models, highlighting that while nausea is a concern, it pales in comparison to the risks of severe sunburn.

Despite the mismatched receptors between humans and mice, some preliminary animal studies showed promise without harmful side effects, suggesting further investigation is warranted.

Considering the rarity of some conditions Smith identified, Schlabach cautioned that the new treatment must offer clear advantages over current options to gain insurance support, which might result in simpler alternatives, such as protective clothing.

Exploring Mechanisms and Future Directions

Panelist Elias Quijano from Northpond Ventures prompted Smith to investigate additional mechanisms of action beyond melanin production, suggesting this could unveil more valuable therapeutic effects. Smith responded that preliminary findings did indicate protective properties against skin cancer aside from mere pigmentation.

Concerns were raised regarding patient experiences with pigmentation, prompting discussions about whether a more adjustable dosing regimen might be necessary if the drug were to be approved for cosmetic use in the future. Smith noted that patients with serious conditions would likely prioritize treatment efficacy over cosmetic concerns.

Trial Strategies and Market Entry

Looking ahead, Chaya Patel from Mission BioCapital inquired about potential trial comparisons against either the existing implant-based treatment or a placebo. Smith expressed enthusiasm for conducting such comparative studies, potentially conducting focused testing in Japan, a country where XP incidence is markedly higher.

Though Smith didn’t emerge from ‘Guppy Tank’ with a sale or a fully formed business entity, the insights gleaned from the investors are poised to assist him and Kruse in navigating the complex pathways of drug development. The event embodies a more nurturing atmosphere for innovators, proving valuable in shaping the future of medical therapies.